Tuning up adjuvant endocrine therapy: the TEAM trial
Mené sur 6 120 patientes ménopausées atteintes d'un cancer du sein HR+ de stade précoce (durée médiane de suivi : 9,8 ans), cet essai international de phase III compare, du point de vue de la survie sans maladie à 10 ans, l'intérêt d'ajouter le tamoxifène à l'exémestane dans le cadre d'un traitement adjuvant
The updated results of the TEAM trial, a randomised, open-label, phase 3 study1 comparing 5 years of exemestane with 2–3 years of tamoxifen followed by exemestane (up to a total of 5 years; sequential group) as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer are reported in The Lancet Oncology by Marloes Derks and colleagues. The study was originally done in nine countries and enrolled 9779 patients.2 Updated outcomes were only available for 6120 patients from six of the countries (63% of the total population).